Table 2.
Vaccine and vaccine type | Recommended dose and administration | References | Median vaccine effectiveness (range) | ||
Vaccine efficacy against | One dose | Two doses | |||
Pfizer/BioNtech (BNT162b2) – mRNA. | Two doses (30 µg, 0.3 mL each) intramuscularly (deltoid) with a recommended interval of 21–28 days between doses. | 160 163–207 | Infection | 51% (-72–91.7%) | 91.15% (25.6%–98.1%) |
Infection – Adolescents | 91.1% | 99.55% (92%–100%) | |||
Infection – Alpha | 59% (47.5%–66%) | 87.5% (67%–97.4%) | |||
Infection – Beta | 60% | 77% (49%–97.4%) | |||
Infection - Gamma | 60% | 77% (61%–84%) | |||
Infection – Delta | 56.5% (35.6%–65.5%) | 80.5% (52.4%–88%) | |||
Hospitalisation | 74% (35%–97%) | 94.8% (85%–99%) | |||
Hospitalisation – Alpha | 81.5% (80%–83%) | 95% | |||
Hospitalisation – Delta | 86% (78%–94%) | 96% | |||
ICU admission/severe infection | 69.65% (62%–77.3%) | 97.3% (86%–99.2%) | |||
Death | 76% (43.95%–96.3%) | 96.72% (91.3–98.6) | |||
Oxford University/ AstraZeneca (AZD1222) - Non-replicating adenovirus viral vector (ChAdOx1). | Two doses (0.5 mL each) intramuscularly (deltoid) with a recommended interval window of 8 to 12 weeks. | 133 165 168 170 171 181 192 202 203 208–219 | Infection | 50% (15%–64%) | 62.9% (-74.2–91.1%) |
Infection – Alpha | 63% (48.7%–64%) | 73% (70.4%–79%) | |||
Infection – Delta | 46% (30%–67%) | 67% (60%–71%) | |||
Hospitalisation | 79.5% (43%–97%) | 90% (69.6%–100%) | |||
ICU admission/severe infection | 54% (53%–62%) | 93% (69.2%–100%) | |||
Death | 86.5% (49.3%–99.2%) | 93% (72.1%–99.8%) | |||
Johnson & Johnson (Ad26.COV2.S) - Recombinant, replication-incompetent adenovirus serotype 26 (Ad26) vector. | One dose (0.5 mL) intramuscularly (deltoid). | 161 179 205 220–224 | Infection | 74.2% (27.4%–91%) | NA |
Hospitalisation | 83.1% (33.5%–95.7%) | NA | |||
ICU admission/severe infection | 81.05% (56%–92.5%) | NA | |||
Death | 69.7% (48.9%–90.5%) | NA | |||
Moderna (mRNA-1273) - mRNA | Two doses (100 µg, 0.5 mL each) intramuscularly (deltoid) with a recommended interval of 28 days between doses. | 162 168 169 173 175 178 179 181 182 195 196 201 205 225–231 | Infection | 81.7% (45.8%–95%) | 86.9% (52.5%–98.6%) |
Infection – Alpha | 82.3% (0%–94%) | 95% (74.7%–99.2%) | |||
Infection – Beta | 47.9% (0%–77%) | 95.3% (94.2%–96.4%) | |||
Infection – Delta | 76% (72%–79.7%) | 83% (50.6%–86.7%) | |||
Hospitalisation | 89% (79%–96%) | 96.2% (91.6%–97.3%) | |||
ICU admission/severe infection | 44.5% (0%–92.1%) | 98.2% (78.6%–100%) | |||
Death | 44.5% (0%–92.1%) | 100% (97.9%–100%) | |||
Sinopharm BBIBP-CorV - Aluminium-hydroxide-adjuvanted, inactivated whole virus vaccine | Two doses (0.5 mL) intramuscularly (deltoid) with a recommended interval of 3 weeks between doses. | 232–237 | Infection | 14.1% (13.8%–15.3%) | 56.85% (45%–78.1%) |
Hospitalisation | −20% | 72% (44.5%–79.8%) | |||
ICU admission/severe infection | 8.4% (3.7%–100%) | 92.2% (69.5%–100%) | |||
Death | 27.9% (25.5%–45.2%) | 92.25% (63%–97.1%) | |||
Sinovac-CoronaVac - Aluminium-hydroxide-adjuvanted, inactivated whole virus vaccine | Two doses (0.5 mL) intramuscularly (deltoid) with a recommended interval window of 2 to 4 weeks. | 115 218 219 232 238–244 | Infection | 46.4 (-0.8–94%) | 49.9% (24.7%–83.5%) |
Hospitalisation | 21.75% (6.5%–40.3%) | 72.6% (39.1%–100%) | |||
ICU admission/severe infection | 45.3% (28.1%–67.74%) | 85.39% (58.1%–100%) | |||
Death | 66.15% (13.1%–99.3%) | 61.2% (48.9%–86.7%) | |||
Bharat Biotech – Covaxin – whole virion inactivated virus vaccine | Two doses (0.5 mL) intramuscularly (deltoid) with a recommended interval window of 28 days. | 216 217 245–247 | Infection | 27.5% (-1–53%) | 68.3% (27%–93%) |
Hospitalisation | 59.5% (43%–76%) | 85.5% (83 – 88) | |||
ICU admission/severe infection | 62% | 93.2% (93%–93.4%) | |||
Novavax – NVX-CoV2373 (Nuvaxovid)orSerum Institute of India – COVOVAX (Novavax formulation - recombinant SARS-CoV-2 S protein nanoparticle as a coformulation with the adjuvant Matrix-M | Two doses (0.5 mL) intramuscularly (deltoid) with a recommended interval of 3–4 weeks. | 248–251 | Infection | NA | 89.3% (49.4%–96.4%) |
This table reports the median (and range) of vaccine effectiveness values from the studies that are outlined in greater detail in the online supplementary table. Values were included for averaging regardless of size of study population, study population age, or time since vaccine, however, these details can be found in the online supplemental table 2.